RT Journal Article
T1 Assessment of the EarlyCDT-Lung test as an early biomarker of lung cancer in ever-smokers: A retrospective nested case-control study in two prospective cohorts.
A1 Wu, Wendy Yi-Ying
A1 Haider, Zahra
A1 Feng, Xiaoshuang
A1 Heath, Alicia K
A1 Tjønneland, Anne
A1 Agudo, Antonio
A1 Masala, Giovanna
A1 Robbins, Hilary A
A1 Huerta, Jose-Maria
A1 Guevara, Marcela
A1 Schulze, Matthias B
A1 Rodriguez-Barranco, Miguel
A1 Vineis, Paolo
A1 Tumino, Rosario
A1 Kaaks, Rudolf
A1 Fortner, Renée T
A1 Sieri, Sabina
A1 Panico, Salvatore
A1 Nøst, Therese Haugdahl
A1 Sandanger, Torkjel M
A1 Braaten, Tonje
A1 Johansson, Mattias
A1 Melin, Beatrice
A1 Johansson, Mikael
K1 EarlyCDT-Lung test
K1 biomarkers
K1 lung cancer
K1 prediagnostic samples
AB The EarlyCDT-Lung test is a blood-based autoantibody assay intended to identify high-risk individuals for low-dose computed tomography lung cancer screening. However, there is a paucity of evidence on the performance of the EarlyCDT-Lung test in ever-smokers. We conducted a nested case-control study within two prospective cohorts to evaluate the risk-discriminatory performance of the EarlyCDT-Lung test using prediagnostic blood samples from 154 future lung cancer cases and 154 matched controls. Cases were selected from those who had ever smoked and had a prediagnostic blood sample
PB John Wiley & Sons, Inc.
YR 2022
FD 2022-10-05
LK http://hdl.handle.net/10668/22117
UL http://hdl.handle.net/10668/22117
LA en
NO Wu WY, Haider Z, Feng X, Heath AK, Tjønneland A, Agudo A, et al. Assessment of the EarlyCDT-Lung test as an early biomarker of lung cancer in ever-smokers: A retrospective nested case-control study in two prospective cohorts. Int J Cancer. 2023 May 1;152(9):2002-2010.
NO Our study was supported by an early detection of cancer development grant from Swedish Department of Health Ministry. The participation of IARC personnel was supported by a programme award from the US National Cancer Institute (NCI U19 CA203654). Part of the study was supported by a generous grant from the Cancer Research Foundation of Northern Sweden (AMP19-962). We thank the Biobank Research Unit at Umeå Universitet, Västerbotten Intervention Programme, the Northern Sweden MONICA study, the Mammography Study and Region Västerbotten for providing data and samples and acknowledge the contribution from Biobank Sweden, supported by the Swedish Research Council (VR 2017-00650). The coordination of EPIC is financially supported by International Agency for Research on Cancer (IARC) and also by the Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London which has additional infrastructure support provided by the NIHR Imperial Biomedical Research Centre (BRC). The national cohorts are supported by: Danish Cancer Society (Denmark); Ligue Contre le Cancer, Institut Gustave-Roussy, Mutuelle Générale de l'Education Nationale, Institut National de la Santé et de la Recherche Médicale (INSERM) (France); Deutsche Krebshilfe, German Cancer Research Center (DKFZ), German Institute of Human Nutrition Potsdam-Rehbruecke (DIfE), Federal Ministry of Education and Research (BMBF) (Germany); Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy, Compagnia di SanPaolo and National Research Council (Italy); Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands (The Netherlands); Health Research Fund (FIS) - Instituto de Salud Carlos III (ISCIII), Regional Governments of Andalucía, Asturias, Basque Country, Murcia and Navarra, and the Catalan Institute of Oncology - ICO (Spain); Cancerfonden, Swedish Research Council and County Councils of Skåne and Västerbotten (Sweden); Cancer Research UK (14136 to EPIC-Norfolk; C8221/A29017 to EPIC-Oxford), Medical Research Council (1000143 to EPIC-Norfolk; MR/M012190/1 to EPIC-Oxford) (United Kingdom). In addition, we thank Kim Overvad from EPIC Aarhus, Demark, and the National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands, for their contribution and ongoing support to the EPIC Study.
DS RISalud
RD Apr 5, 2025